Cargando…
Role of cytokine therapy for renal cell carcinoma in the era of targeted agents
Starting in the late 1980s, cytokines were considered the mainstay of treatment for locally advanced or metastatic renal cell carcinoma (rcc) because of a lack of improved survival with either chemotherapy or hormonal therapy alone. The cytokine agents interferon alfa (ifnα) and interleukin-2 (il-2)...
Autores principales: | Koneru, R., Hotte, S.J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687800/ https://www.ncbi.nlm.nih.gov/pubmed/19478896 |
Ejemplares similares
-
Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022) -
Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era
por: Scheipner, Lukas, et al.
Publicado: (2023) -
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
por: Kapoor, A., et al.
Publicado: (2009) -
Targeted therapies for renal cell carcinoma: more gains from using them again
por: Gan, H.K., et al.
Publicado: (2009) -
Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)